TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8379860
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran injections (5 injections spaced 4 weeks)
Study: 3093556
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 2 mg
Study: 3093556
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 10 mg
Study: 2932989
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium 20 mg
Study: 22233510
Drug: Op Volle
Normalized name: Schinus molle pollen
DrugBank: Schinus molle pollen (DB10483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Op Volle Kracht (OVK) intervention, consisting of 16 lessons of 50 min each, incorporating Cognitive Behavioral Therapy, social skills training, problem solving, and decision making.
Study: 20579510
Drug: Extended-release fluvoxamine
Normalized name: fluvoxamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release fluvoxamine (fluvoxamine ER) 100 mg/d, titrated to 100-300 mg/d
Study: 20579510
Drug: Extended-release fluvoxamine
Normalized name: fluvoxamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release fluvoxamine (fluvoxamine ER) during 40-week open-label extension
Study: 16104906
Drug: Low-dose thalidomide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose thalidomide (200 mg)
Study: 16104906
Drug: High-dose thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose thalidomide (800 mg to 1200 mg)
Study: 12559480
Drug: 200‐mg L‐5‐hydroxytryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg L‐5‐hydroxytryptophan
Study: 2242106
Drug: Phenobarbital (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (4 to 5 mg per kilogram of body weight per day)
Study: 2242106
Drug: Phenobarbital (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (after tapering and discontinuation)
Study: 400110
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg three times daily for 10 days
Study: 400110
Drug: Cefuroxime 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1000 mg three times daily for 10 days
Study: 30521129
Drug: PUR0200 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR0200 (3 μg tiotropium)
Study: 30521129
Drug: Spiriva HH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva HH (18 μg)
Study: 26991917
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + 0.8 mg folic acid
Study: 26991917
Drug: Enalapril +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril + 0.8 mg folic acid (MTHFR TT genotype with low folate levels)
Study: 24352403
Drug: Intensified, NT-proBNP-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified, NT-proBNP-guided therapy
Study: 15840990
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg
Study: 23053645
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg and 900 mg
Study: 19775450
Drug: Olanzapine (O)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on days 2‐5
Study: 19775450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2‐5)
Study: 11402109
Drug: Low-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose botulinum toxin type A (50 U)
Study: 11402109
Drug: High-dose botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose botulinum toxin type A (100 U)
Study: 9250554
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 180 mg once/day
Study: 3536495
Drug: All dietary
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dietary treatments
Study: 30289569
Drug: Peri-implant mucositis
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant mucositis
Study: 30289569
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with bone level ≥2 mm without BOP
Study: 30289569
Drug: Peri-implant diseases
Normalized name: PAD,PERI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant diseases overall
Study: 22153132
Drug: Fentanyl 0
Normalized name: fentanyl 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0 μg with 0.17% ropivacaine 12 mL
Study: 22153132
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg with 0.17% ropivacaine 12 mL
Study: 22153132
Drug: Fentanyl 75
Normalized name: FENTANYL 75MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 75 μg with 0.17% ropivacaine 12 mL
Study: 22153132
Drug: Fentanyl 100
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 100 μg with 0.17% ropivacaine 12 mL
Study: 20669311
Drug: CEP-1347 (antiapoptotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-1347 (antiapoptotic agent)
Study: 17179874
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of a treatment fidelity instrument
Study: 15883277
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for choroidal melanoma
Study: 11873007
Drug: Zidovudine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (300 mg)
Study: 9876212
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF) for 5 days
Study: 9876212
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF)
Study: 6994679
Drug: Conventional topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical chemotherapeutic agent
Study: 23062523
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care plus 6 months of daily educational text messages
Study: 17713334
Drug: Fluoridated food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated food item (0.5 mg fluoride cookie, 3 times daily)
Study: 17713334
Drug: Placebo food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo food item (cookie, 3 times daily)
Study: 15025742
Drug: Trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (160 mg orally twice daily for 3 days)
Study: 10192751
Drug: Topical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical heparin
Study: 31951279
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg weekly
Study: 15494617
Drug: Rivastigmine 6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6 to 12 mg/day
Study: 11120577
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% ophthalmic solution
Study: 8922004
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine (4 mL)
Study: 1556948
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic diet (600 kcal/d, 8 g nitrogen/d)
Study: 1556948
Drug: Nonketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonketogenic diet (600 kcal/d, 8 g nitrogen/d)
Study: 26840338
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing intervals
Study: 26840338
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing intervals
Study: 19733827
Drug: Substitute products
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitute products (drugs in the same therapeutic class)
Study: 15132375
Drug: Small incision
Normalized name: Seprafilm Small Incision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small incision trabeculectomy avoiding Tenon's capsule (SIT)
Study: 9040628
Drug: Aerosolized cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized cyclosporine A (300 mg) for 10 consecutive days followed by maintenance of 3 days per week
Study: 9040628
Drug: Conventional rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rescue therapy
Study: 7702337
Drug: Buflomedil infusion
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil infusion during arteriographies
Study: 3312030
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g b.i.d.)
Study: 3312030
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g t.i.d. or more)
Study: 30476916
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (CaD) 500 mg, administered orally, 3 times per day for 3 months
Study: 27434036
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment for progressive disease
Study: 22139410
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g of pure βA reference solution (REF)
Study: 22139410
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g in slow-release βA tablets (TAB)
Study: 12162502
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg SCT intravenous infusion
Study: 10467531
Drug: Naftidrofuryl (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (three 200-mg tablets per day)
Study: 27932229
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily during weeks 1-3 of each 4-week cycle
Study: 27932229
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily during weeks 1-3 of each 4-week cycle
Study: 26052973
Drug: Vasopressin, steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin, steroids, and epinephrine (VSE) protocol
Study: 15055892
Drug: Intramuscular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular treatment with clonidine 2 microg kg(‐1)
Study: 15055892
Drug: Block treatment
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block treatment with clonidine 2 microg kg(‐1)
Study: 9335410
Drug: benazepril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril, 10 mg, plus placebo (BZ10)
Study: 9335410
Drug: benazepril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril, 10 mg, plus amlodipine, 2.5 mg (BZ10/AML2.5)
Study: 9335410
Drug: benazepril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril, 10 mg, plus amlodipine, 5 mg (BZ10/AML5)
Study: 8227238
Drug: Mailed medication-refill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed medication-refill reminders
Study: 8227238
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mailed medication-refill reminders and unit-of-use packaging
Study: 3804025
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (0.5 mg/patch)
Study: 3804025
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of transdermal scopolamine and cimetidine
Study: 21558517
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa (60,000 U)
Study: 19299145
Drug: Intra-articular cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular cocktail analgesic injection (morphine, bupivacaine, betamethasone)
Study: 19299145
Drug: Intra-articular cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular cocktail analgesic injection
Study: 15545167
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Study: 15545167
Drug: Soy oil
Normalized name: Hydrogenated soy oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Study: 8761384
Drug: Elactocin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elactocin (various infusion schedules: 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly, continuous 5 day intravenous infusion)
Study: 2865326
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of clorazepate at bedtime for two weeks
Study: 24716586
Drug: tofacitinib 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 2, 5 or 15mg twice daily
Study: 17371601
Drug: Goal Directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal Directed Therapy (GDT)
Study: 18481290
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg BHT‐3009
Study: 16514109
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (nasal, 4 L . min(‐1))
Study: 14696019
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 week baseline followed by 3 weeks treatment)
Study: 11136301
Drug: Cilnidipine 10
Normalized name: Cilnidipine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine 10 mg orally for 7 days
Study: 4061800
Drug: Diazepam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.75 mg/kg rectally
Study: 4061800
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of diazepam 0.5 mg/kg, morphine 0.15 mg/kg, and hyoscine 0.01 mg/kg rectally
Study: 19743516
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (no ATRA)
Study: 19743516
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (both ATRA and conventional chemotherapy)
Study: 17385465
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication and free-load bicycle exercise (FBE)
Study: 17385465
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication only
Study: 15078738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no change in normal daily activities)
Study: 31399742
Drug: Pair-feeding group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pair-feeding group (PF, 21 ± 1°C, pair-feeding on the daily feed intake of HT hens)
Study: 21696894
Drug: Cocaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (30 mg i.v.)
Study: 29629852
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice a day
Study: 29629852
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg twice a day plus zidovudine and lamivudine
Study: 29658256
Drug: Bushen Daozhuo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Daozhuo Granules (BDG) at 200 ml bid for 4 weeks
Study: 29738183
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd for 4 weeks
Study: 12895211
Drug: Conventional steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroids
Study: 11118461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a)
Study: 11118461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a) with continuous infusion of fluorouracil (FU)
Study: 7507638
Drug: diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 120 or 240 mg/day
Study: 7507638
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 or 200 mg/day
Study: 7507638
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 or 20 mg/day
Study: 7507638
Drug: hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide 50 or 100 mg/day
Study: 2311806
Drug: Parenteral pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral pethidine
Study: 24021043
Drug: Gastrointestinal prokinetic
Normalized name: GASTROINTESTINAL MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal prokinetic drug (placebo)
Study: 21741344
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment for at least 3 years
Study: 19466986
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg (once daily for 7 days) + Diclofenac 50 mg (three times daily for 7 days)
Study: 19466986
Drug: Aspirin 30
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 30 mg (once daily for 7 days)
Study: 19466986
Drug: Aspirin 80
Normalized name: aspirin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 80 mg (once daily for 7 days) + Ibuprofen 800 mg (three times daily for 7 days)
Study: 15257094
Drug: Selective p38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective p38 MAP kinase inhibitor drug, RWJ‐67657 (single oral dose administered 30 min before endotoxin infusion)
Study: 15257094
Drug: Placebo (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single oral dose administered 30 min before endotoxin infusion)
Study: 11140429
Drug: Intravenous FP
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous FP (250 microg)
Study: 30167752
Drug: FNB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNB with posterior capsule injection (PCI)
Study: 28388890
Drug: 1500 ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 ml, 1000 ml, 500 ml, or 250 ml bottle sizes of cola
Study: 11228204
Drug: Oocytes cryopreserved
Normalized name: cryopreserved human liver cells
DrugBank: cryopreserved human liver cells (DB05852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oocytes cryopreserved with sucrose concentration of 0.2 mol/l
Study: 11228204
Drug: Oocytes cryopreserved
Normalized name: cryopreserved human liver cells
DrugBank: cryopreserved human liver cells (DB05852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oocytes cryopreserved with sucrose concentration of 0.3 mol/l
Study: 11228204
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) of thawed oocytes
Study: 26038524
Drug: Evidence-based medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medications after acute myocardial infarction
Study: 26038524
Drug: Provider explained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider explained potential side effects of medications
Study: 26334761
Drug: Lower medication
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower medication adherence
Study: 23625188
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg/day with 100 mg mirabegron OCAS
Study: 23625188
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg/day with 100 mg mirabegron OCAS
Study: 23625188
Drug: Mirabegron 160
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 160 mg immediate release in poor metabolizers
Study: 23625188
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 and 100 mg OCAS in different CYP2D6 phenotypes
Study: 17112810
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole plus 20 mg famotidine (full-concomitant regimen)
Study: 17112810
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole alone
Study: 17112810
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine alone
Study: 15701218
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.4% ophthalmic solution